Sam Brusco, Associate Editor03.30.22
Medtech contract research organization NAMSA will acquire Medanex Clinic, a Belgian European preclinical research organization.
Medanex’s team of internationally renowned cardiovascular surgeons and staff guide clients through preclinical study design. Large companies and small research groups partner with Medanex for cardiovascular services and timely, efficacious study outcomes.
“NAMSA is very excited to expand its European preclinical services with the addition of Medanex,” Dr. Christophe Berthoux, CEO of NAMSA told the press. “Their robust preclinical capabilities and expertise, specifically in the cardiovascular arena, will help enhance the NAMSA client experience. We are pleased to partner with an organization that strongly shares our core values and drive to accelerate medical device development throughout the world.”
NAMSA’s preclinical research services support all model types, treatments, and implant requirements. The firm offers full continuum development services, including regulatory, reimbursement, quality, and clinical research services.
“Medanex is proud to become a part of the NAMSA Family. With a similar vision to deliver world class expertise and exceptional service and resources to the medical device industry, we are ideally aligned. For 12 years, we’ve grown to become a trusted and respected partner for the most challenging surgical studies while remaining customer-oriented and striving for scientific excellence,” said Medanex CEO Hadewych Van Hauwermeiren. “With the complementary expertise and resources of NAMSA, we will serve our clients in an even greater capacity and look forward to joining the world’s leading CRO for cardiovascular research.”
Acquiring Medanex will grow NAMSA’s scale in Europe and growing global footprint, now service clients in 20 locations across the Americas, Asia-Pacific, and Europe.
Medanex’s team of internationally renowned cardiovascular surgeons and staff guide clients through preclinical study design. Large companies and small research groups partner with Medanex for cardiovascular services and timely, efficacious study outcomes.
“NAMSA is very excited to expand its European preclinical services with the addition of Medanex,” Dr. Christophe Berthoux, CEO of NAMSA told the press. “Their robust preclinical capabilities and expertise, specifically in the cardiovascular arena, will help enhance the NAMSA client experience. We are pleased to partner with an organization that strongly shares our core values and drive to accelerate medical device development throughout the world.”
NAMSA’s preclinical research services support all model types, treatments, and implant requirements. The firm offers full continuum development services, including regulatory, reimbursement, quality, and clinical research services.
“Medanex is proud to become a part of the NAMSA Family. With a similar vision to deliver world class expertise and exceptional service and resources to the medical device industry, we are ideally aligned. For 12 years, we’ve grown to become a trusted and respected partner for the most challenging surgical studies while remaining customer-oriented and striving for scientific excellence,” said Medanex CEO Hadewych Van Hauwermeiren. “With the complementary expertise and resources of NAMSA, we will serve our clients in an even greater capacity and look forward to joining the world’s leading CRO for cardiovascular research.”
Acquiring Medanex will grow NAMSA’s scale in Europe and growing global footprint, now service clients in 20 locations across the Americas, Asia-Pacific, and Europe.